Scientists in Australia have developed a method for the rapid synthesis of safe vaccines, an approach that can be used to test vaccine strategies against novel pandemic pathogens such as SARS-CoV-2, the virus that causes COVID-19.
Led by Professor Richard Payne at the University of Sydney and Professor Warwick Britton at the Centenary Institute, the team has demonstrated application of the method with a new vaccine for use against tuberculosis (TB), which has generated a powerful protective immune response in mice.
Researchers are keen to develop the vaccine strategy further to assist in the rapid pre-clinical testing of new vaccines, particularly for respiratory illnesses.
“Tuberculosis infects 10 million and kills more than 1.4 million people every year,” said joint first author Dr. Anneliese Ashhurst from the University of Sydney. “Historically, it is the leading cause of death worldwide from a single infectious agent. So far, a TB vaccine that is highly effective and safe to use in all populations has eluded medical science.”
The only current vaccine for tuberculosis, the Bacille Calmette-Guerin vaccine, uses an injected live bacterium. It is effective in infants but has reduced effectiveness in adolescents and adults and poses significant health risks for immunocompromised patients, particularly for people living with HIV/AIDS.
Protein-based vaccines have been shown to be very safe, but they must be mixed with enhancers, or adjuvants, to make them effective, which is not straightforward.
Dr. Ashhurst said: “The challenge is to ensure that our immune cells see both the protein and adjuvant simultaneously. To overcome this difficulty, for the first time we have developed a method that synthesizes the protein with an attached adjuvant as a single molecule.”
The vaccine strategy and synthetic technology could be deployed to rapidly generate new vaccines for pre-clinical testing for a range of diseases, the researchers say, including the respiratory pathogen that causes COVID-19.
Their results are published today in the Proceedings of the National Academy of Sciences.
How it works
In order for vaccines to be effective, they need to stimulate behavior in protective T-cells that allows them to recognize the pathogen as an antigen, or foreign body. In the case of tuberculosis, our immune system needs to respond quickly to the bacteria that causes TB—Mycobacterium tuberculosis—to reduce infection in lungs.
Using the method developed by the Sydney scientists, an inhaled vaccine provides a low-dose immune-stimulating molecule—containing a synthesised bacterial protein attached directly to an adjuvant—to the immune cells in the lungs.
A major hurdle overcome by the scientists was the difficulty in fusing hydrophobic (water-repellent) adjuvants with a water-soluble protein antigen.
“We got around this problem of keeping hydrophobic and hydrophilic molecules together in a vaccine by developing a way to permanently bind the protein and adjuvant together as a single molecule using synthetic chemistry. Our approach overcomes the solubility problems faced by other methods,” said Professor Payne from the School of Chemistry and Deputy Director of the ARC Centre for Innovations in Peptide & Protein Science (CIPPS).
The team says that synthesizing an entire bacterial protein with attached adjuvant has not been achieved before.
Professor Britton from the Tuberculosis Research Program at the Centenary Institute said: “As well as providing a rapid method to develop a range of vaccines for pre-clinical testing, we expect that this pulmonary vaccination approach will be particularly beneficial for protecting against respiratory diseases.”
He said: “We hope that an inhaled vaccine for tuberculosis using a protein-based immunization will allow us to develop a universal and safe approach to combatting this deadly disease.”
The other major advantage with this method is that vaccines for a range of diseases can be developed rapidly and safely in the laboratory.
“We don’t need to grow the actual pathogen in the lab to make the vaccine,” said Dr. Ashhurst, who holds a joint position in the School of Chemistry and the School of Medical Sciences. “Using this new method, we can rapidly and safely synthesize highly pure vaccines in the lab and take them straight into animal models for pre-clinical testing.”
New vaccine targets killer disease tuberculosis
Cameron C. Hanna el al., “Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice,” PNAS (2020). www.pnas.org/cgi/doi/10.1073/pnas.2013730118
New method to assist fast-tracking of vaccines for pre-clinical tests (2021, January 18)
retrieved 18 January 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022